Tag: QoL

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 94

Ide-cel in R/R myeloma: patient-reported outcomes and resistance

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 97

DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...

  Feb 03 2021 Tagged MM, mAbs, QoL

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.

Visit website